Halozyme Therapeutics Inc. Common Stock (HALO)

FairStock Score: 51/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for simple, recurring revenue streams and conservative prices. Halozyme is a narrow but valuable platform: its patented rHuPH20 enzyme helps other injectable biologics get delivered. The latest filed results show excellent economics. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $481.0M, net income $229.9M, and diluted EPS $1.90, up from revenue of $325.7M, net income of $165.2M, and diluted EPS of $1.33 in fiscal Q2 2025, the quarter ended 2025-06-30. That is strong growth and a 47.8% net margin. Trailing free cash flow is $518.5M, a 4.2% FCF yield on the 2026-10-13 market cap of $12.4B. FairStock's Piotroski F-Score is 7/9 and Altman Z-Score is 3.98, so the balance sheet does not look fragile. But price matters. At the 2026-10-13 close of $109.62, FairStock's P/E is 32.15, P/B is 87.00, EV/EBITDA is 20.08, and PEG is 1.19. The Graham Number is only $9.83, leaving a margin of safety of -1015.16%. I see a high-quality, cash-generative business, but the market is already paying up for it. The five-year Lynch category is STALWART, with profit growth of 19.7% a year and revenue growth of 39.2%, yet in fiscal year 2025, the year ended 2025-12-31, net income was $316.9M versus $444.1M in fiscal year 2024, the year ended 2024-12-31. So the trend is not perfectly smooth. The business looks strong; the stock looks full. I would want a wider discount before calling it a bargain.

In plain English: Halozyme makes a special enzyme that helps other injectable medicines get into the body more easily, and it earns money from its products and related technology. Recent quarters show strong sales and profits, and the company produces plenty of cash. But the stock price looks expensive compared with its accounting value and a conservative value estimate based on its earnings and assets.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer